CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Developmen... (xcited by the extent of activitywe have ...)

CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs

Date:8/19/2007

xcited by the extent of activity we have seen with belinostat in combination with carboplatin and paclitaxel, and look forward to further assessing the activity of the combination from the maturing data in recurrent ovarian cancer and transitional cell cancer of the bladder."

Belinostat in combination with idarubicin against Acute Myelogenous Leukemia (AML):

A Phase I/II clinical trial evaluating belinostat in combination with the idarubicin for the treatment of AML is being initiated at multiple sites in the EU. Patients under the age of 60 with relapsed or refractory AML, or patients over 60 with newly diagnosed or previously treated AML, are eligible for enrollment in the trial. Up to 70 patients will be enrolled and receive intravenous treatment in one of two regimens. Patients will either receive intravenous belinostat administered once daily for five days in combination with idarubicin or a continuous infusion of belinostat with or without idarubicin. Enrollment into the treatment arms will occur in parallel to define the maximum tolerated dose (MTD) for each treatment regimen.

CR011-vcMMAE Phase I/II trial for the treatment of metastatic melanoma:

Enrollment in the Phase I dose-escalation trial to determine the maximum tolerated dose (MTD) of CR011-vcMMAE in patients with unresectable Stage III or IV metastatic melanoma is ongoing. Upon establishment of the MTD, the trial will be advanced into Phase II to further define the safety and efficacy of CR011-vcMMAE. CuraGen anticipates presenting Phase I dose-escalation results in the fourth quarter of 2007.

Reiterating 2007 Financial Guidance and Expectations for 2008

The following statements are based on CuraGen's current expectations. These statements are forward-looking and actual results may differ materially. Please see the note regarding Forward-Looking Statements in this release for a description of certain important risk factors that could cause actual results to differ
'/>"/>

SOURCE CuraGen Corporation

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
5. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
6. XTL Provides Update on Phase I Clinical Trial of XTL-2125
7. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
8. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
9. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
10. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
11. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform

Post Your Comments:

CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Developmen...(xcited by the extent of activitywe have ...),Health